ADC reports Phase I data for ADCT-402 in NHL

ADC Therapeutics S.A. (Epalinges, Switzerland) reported interim data from 68 evaluable patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) in the dose-escalation portion of the Phase I ADCT-402-101 trial showing that IV ADCT-402 (loncastuximab tesirine, Lonca-T) at doses of ≥120 μg/kg led to an overall response rate (ORR) of 60%, including 24 complete responses and 17 partial responses, plus seven cases of stable disease. Median duration of response and progression-free survival (PFS) were 5.3 and 4.8 months, respectively.

In 49 evaluable patients with diffuse large B cell lymphoma (DLBCL), ADCT-402 at doses of ≥120 μg/kg led to an ORR of 55%, including 18 complete responses and nine partial responses, plus five cases of stable disease. Median duration of response and PFS were 4.9 and 3.5 months, respectively. Data were presented at the American Society of Hematology meeting in Atlanta...